GT Biopharma Announces Interim GTB-3550 Trike™ Monotherapy Clinical Trial Results At 2021 Raymond James Human Health Innovation Conference

BEVERLY HILLS, Calif.: BEVERLY HILLS, Calif., June 23, 2021 /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary NK cell engager (TriKE™) protein biologic technology platform, announced Jeffrey S. Miller, M.D., Deputy Director of the Masonic Cancer...

Click to view original post